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ABSTRACT 
This article reviews the last decade 
studies on the economic impact of an-
kylosing spondylitis (AS). Interestingly, 
a common observation is that in AS in-
direct costs are higher than the use of 
direct healthcare resources.  
Country, age, gender, and severity of 
the diseases impact on per patient an-
nual costs AS related. 
Different payment and reimbursement 
regimes may impact on the amount and 
distribution of indirect costs. The dif-
ferences observed among countries on 
absolute and relative (compared with 
direct costs) amounts of indirect costs 
can be explained with the capability of a 
country of actually measure productivity 
losses and indirect costs. Low indirect 
costs without other indicators should not 
be considered as a sign of efﬁciency in 
AS care, but may be due to an underes-
timation of AS-related costs; as a conse-
quence, indirect costs may be a net loss 
for patients that nobody can repay. 
A private insurance reimbursement re-
gime has the highest capability of in-
ducing players to deﬁne, select and ac-
tually identify indirect costs better than 
in different reimbursement regimes. 
Therefore indirect costs may become 
very high in case of private insurance 
regimes because of their more detailed 
identiﬁcation. 
Introduction
Ankylosing spondylitis (AS) is a rheu-
matic disease with a socio-economic 
impact for the patient, the healthcare 
system and the society. This disease 
determines an increased healthcare 
utilisation, formal and informal care, 
and a reduced productivity or working 
ability of patients. The impact of AS 
on patient’s life is meaningful from a 
clinical as well as an economic point of 
view but also in terms of quality of life. 
In fact, literature data show that AS pa-
tients are worried mainly about work 
ability, social relationships and family 
life. From the economic perspective, 
the main cost driver is represented by 
decreased physical function (1). 
The objective of this systematic litera-
ture review is to establish the economic 
impact of AS. The review is based on 
papers published over the last decade 
and is designed in accordance with the 
recommendations of the Centre for Re-
views and Dissemination (2) and of the 
Cochrane Collaboration (3), thereby us-
ing an established rigorous and repro-
ducible methodology. A protocol was 
developed to deﬁne review questions.
Methods
Published studies in English were 
searched using the main electronic 
database, PubMed MEDLINE. The 
search was performed for the period 
January 2002–September 3, 2012. The 
search strategy is as follows: ((“econom
ics”[Subheading] OR “economics”[All 
Fields] OR “cost”[All Fields] OR “costs 
and cost analysis”[MeSH Terms] OR 
(“costs”[All Fields] AND “cost”[All 
Fields] AND “analysis”[All Fields]) OR 
“costs and cost analysis”[All Fields]) 
AND (“spondylitis, ankylosing”[MeSH 
Terms] OR (“spondylitis”[All Fields] 
AND “ankylosing”[All Fields])OR 
“ankylosing spondylitis”[All Fields] 
OR (“ankylosing”[All Fields]AND 
“spondylitis”[All Fields]))) AND 
((“2002/01/01”[PDAT]: “2012/09/03”-
[PDAT]) AND “humans”[MeSH 
Terms] AND English[lang] AND 
“adult”[MeSH Terms]).
The publications were assessed for in-
clusion by a 3-step process: 
i. titles and abstracts of all identiﬁed 
studies were assessed by one reviewer 
and checked by a second reviewer; 
ii. full texts of relevant articles were 
then obtained and inclusion criteria ap-
plied independently by two reviewers. 
Possible discords between reviewers 
were resolved by consensus; 
iii. data were extracted by one reviewer 
and then checked by a second reviewer.
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Inclusion criteria
In the study protocol the reviewers se-
lected publications from the mentioned 
database as follows:
Period: Jan. 2002–Sep. 3, 2012
Language: English
Studies: all articles related to economic 
analysis
Patients: adult ≥18 
Outcomes: direct costs, indirect costs, 
and quality of life costs
Exclusion criteria
The studies not published in English 
and all papers published before 2002 
have been excluded from this review. 
Conferences proceedings, case reports, 
reviews, systematic reviews, letters and 
commentaries were also excluded.
Results
As of September 3, 2012, 68 articles 
were extracted by the search procedure. 
These were reduced to 50 articles af-
ter title scrutiny. After abstract review, 
22 publications were included in the 
analysis. These 22 publications were 
examined and assessed for eligibil-
ity. On reading the full text copies, 15 
publications were considered relevant 
to the review (Fig. 1). Two reviewers 
read and examined the full text of these 
publications. 
None of the articles provided a full eco-
nomic evaluation (Cost Minimisation 
Analysis, Cost Effectiveness Analysis, 
Cost Utility Analysis and Cost Beneﬁt 
Analysis). The review (see Table I for 
more details) is based on 6 studies from 
The Netherlands (4-9), 2 from UK (10, 
11), 1 from USA (12), 1 from Sweden 
(13), 1 from Spain (14), 1 from Tunisia 
(15), 1 from Hong Kong (16), 1 from 
Brazil (17), 1 from Germany (18).
Four articles are prospective (4, 5, 6, 
12), 4 are retrospective (10, 14, 15, 
16), 4 are observational (9, 11, 13, 17), 
1 study reports data coming from ran-
domised trials (7), 1 study presents data 
deriving from a longitudinal study (8), 
1 article does not specify (18). 9 studies 
analyse direct and indirect costs (7, 11-
18); 3 articles report only direct costs 
(6, 8, 10), 2 studies report only indirect 
costs (4, 9), 1 article reports healthcare 
and non-healthcare costs, and income 
loss due to days of absence from work 
adopting the patient’s perspective (5). 
Of the 7 articles excluded, 2 studies 
compare pharmacological treatments 
(19, 20), 2 studies are review (21, 22), 
and 3 articles do not include costs (23, 
24, 25).
The burden of AS and its 
societal costs 
The studies included in the economic 
review present direct, indirect and 
quality of life costs related to AS.
The studies that analyse direct and in-
direct costs report very different values 
but all agree on the fact that the societal 
impact of AS is mainly related to non 
direct medical cost. 
The importance of indirect costs is 
shown in different studies. Ward et al. 
(12) observed in a study assessing the 
composition, distribution and drivers 
of societal costs of AS, that, while an-
nual AS related direct costs in the ﬁrst 
year amount to $1,775 vs. $2,674 of di-
rect health costs for all causes, indirect 
costs are about $4,945. 
In the ﬁrst year, AS-related and all cause 
costs for total outpatient care are in a ra-
tio of 1 to 1.25; total hospital care of 1 
to 2.7; diagnostic testing of 1 to 1.056; 
medication of 1 to 1.4. 
Over a period of 5 years, cumulative 
AS related costs per patient are $31,766 
with an average per year of $6,353, of 
these $23,418 are represented by indi-
rect costs. 
The most important predictor for high 
costs both in the ﬁrst and in the ﬁfth 
year is functional disability. Women 
have a higher probability than men to 
have high cumulative healthcare costs 
(gender factors matter in producing 
high cumulative heath costs). 
Similarly Younes et al. (15) evaluated 
the impact of AS and its cost drivers 
through a retrospective study conduct-
ed in Tunisia on 50 AS Patients fol-
lowed over the period March-Septem-
ber 2006. 
With respect to direct medical costs 
they calculate €266.295 per patient 
per year. This result includes, among 
others, €107.218 for systemic medica-
tions, €1.369 for local treatments (i.e. 
intra-articular glucocorticoid therapy), 
€3.648 for osmic acid synovectomy 
therapy, €18.811 for physical thera-
py, €13.661 for surgery, €80.28 and 
€18.75 for inpatient and outpatient 
care, respectively, and €23.906 of cost 
of radiographs. Indirect costs are near 
€279.625 per year per patient overall, 
Fig. 1. PRISMA 
ﬂow diagram for 
cost studies in AS.
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on average, about €1165.5 per patient 
on sick leave and €411.375 per work-
ing patient. 
Analysing factors affecting direct medi-
cal costs, these authors observe that, with 
increasing disease duration, the major 
cost drivers are represented by worse 
quality of life, while no correlation was 
found between costs, age, and sex. 
With respect to indirect costs, the prob-
ability of job absence for an employee 
with AS appears higher for patient aged 
40 year old or more, married, and suf-
fering by AS for 10 years and more. 
Boonen et al. (9) evaluated the impact 
(in terms of sick leave and presentee-
ism) of AS on work productivity in The 
Netherlands. The authors evaluated the 
impact of age, disease duration from di-
agnosis, sex, education, manual or non-
manual profession; having partial work 
disability impact on the probability of 
sick-leave, presenteeism, restriction in 
unpaid work and need for help for un-
paid tasks. 
These authors observe that 73% (80% 
in term of days) of cases of sick leave 
were associated with AS. 
This means €1451 for friction costs 
AS-related (€1982 for men and €257 
for women) and €967 as the cost of ex-
tra hours to compensate for inefﬁcient 
work (€1078 for men and €717 for 
women).
Other studies have evaluated in de-
tail direct medical costs for employed 
people with AS. Strombeck et al. (13) 
assessed the incremental cost for AS 
employees with respect to the general 
population, from a public payer per-
spective. The analysis is focused on 
AS patients aged <66 years in 2007, 
followed between 1993 and 2006, and 
living in Southern Sweden. The study 
involves 116 patients (97 men and 19 
women), of these, during the 3-year 
follow up period, 25 were treated with 
TNF inhibitors. 
Health care costs related with AS were 
$37095 vs. $11071 for no AS employ-
ees. 
Splitting the costs, the authors calcu-
late $3277 vs. $1023 on average of 
total direct costs for AS and no AS 
patient, respectively; $3277 vs. $1023 
for inpatient care; $4299 vs. $1754, re-
spectively for care delivered by physi-
cians; $658 vs. $226 for physiotherapy; 
$8479 vs. $979 for pharmacological 
therapy. Sickness beneﬁt and work dis-
ability amount to $5982 vs. $ 2131 and 
$13636 vs. $3774, respectively. In de-
tail, anti TNF drug treatment amounts 
to $31859. 
Reducing the variability of the costs 
(excluding the 5% of patients with the 
lowest and highest costs), Strombeck 
et al. (13) observe that the three-year 
total costs for AS and non AS employ-
ees shift from $37095 to $34876 vs. 
$11071 to $7427, respectively. 
Comparing a subset of AS treated with 
TNF inhibitors with respect to not treat-
ed patients, these authors also show 
that the 3 year period costs for TNF 
drugs are about $31,859. However the 
sickness compensation and in general 
indirect costs (e.g. days lost, cost of 
sickness compensation i.e. disability 
pension) are lower for patients treated 
with TNF inhibitors. The 3-year total 
costs for treated patients (two times the 
3-year costs associated non treated pa-
tients) mainly depend on drug costs. 
As a general conclusion of their con-
tribute, these authors claim that costs 
for the public payers associated with 
AS are about 3 times higher than the 
costs for the general population. They 
also attest that indirect costs are the 
most important driver of total costs.
Similar results were obtained in differ-
ent countries by Torres et al. (17) and 
Zhu et al. (16). 
Torres et al. (17) examined total annual 
direct and indirect costs related to Bra-
zilian AS patients. In this study, direct 
and indirect costs per patient per year 
are $2065.15 and $2531.76, respectively. 
As observed, annual direct and indi-
rect costs weight 45% and 55% of total 
costs, respectively. Similarly, Zhu et al. 
(16) afﬁrm that the major cost driver is 
represented by indirect costs as of an 
annual total cost amounting to $9120 
62% is represented by indirect costs. 
The important impact of AS in terms 
of work disability, sick leave, and loss 
of productivity is underlined by Boo-
nen et al. (4) comparing data from The 
Netherlands, France, and Belgium. The 
days of sick leave per working patient 
per year are higher in The Netherlands 
compared with France and Belgium 
(18.5 days vs. 6.0 and 9.2). Applying 
the Friction Cost Method to patients 
with paid work, the mean costs per pa-
tient per year are higher in The Neth-
erlands versus France and Belgium, 
respectively €1257 versus €428 and 
€476. Considering the absence from 
paid work and productivity costs for all 
patients (The Netherlands: 130, France: 
53, Belgium: 26), the days absent from 
paid work for all patients are 8.2, 4.5, 
and 5.3, respectively in The Nether-
lands, in France, and in Belgium. Fric-
tion costs for all patients are €557 in 
The Netherlands, €324 in France, 
and €274 in Belgium. The costs with 
Human Capital Approach amount to 
€8862 in The Netherlands, €3188 in 
France, and €3609 in Belgium. The 
study highlights the differences among 
the countries that may be attributed to 
different organisational systems of so-
cial security.
A recent study of Raﬁa et al. (11) evalu-
ates the amount of healthcare resources 
consumed, productivity losses AS-re-
lated and the relationship between the 
severity of AS and total costs. 
The study recruits 1000 AS patient from 
registries of Secondary Care Rheuma-
tology in the UK through two postal 
questionnaires in the interval of three 
months. Direct costs AS related are due 
to medications, disease-modifying anti-
rheumatic drugs and anti-TNF drugs, 
length of hospitalisations, outpatients 
and General Practitioner (GP) visits, 
physiotherapy and hydrotherapy treat-
ments. 
Over a three-month period, direct and 
indirect costs AS-related sum £1330.56 
and £4839.70, respectively. Differenc-
es are observed when patients are sub-
divided on the basis of disease severity, 
in fact direct costs for patients with low 
and high severity of AS are £305.63 vs. 
£595.41, respectively. 
With respect to indirect costs, the mon-
etary quantiﬁcation of productivity 
losses is £1,014.56 and £ 4148.05, for 
low and high severity. 
The leitmotif shared by this article and 
the above analysed is that AS severity 
and non medical indirect costs play a 
fundamental role in the societal costs of 
AS in terms of productivity losses. Ko-
belt et al. (14) also observed an increase 
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of costs related to disease severity as 
measured with BASDAI and BASFI 
(Bath AS functional and disease activ-
ity indexes): costs increase from €4260 
at BASFI of 1 to €78300 at BASFI of 
10; and from €11600 at BASDAI of 1 
to €18900 at BASDAI of 10. The au-
thors estimate that the total annual costs 
per patient amount to €20328 of which 
66.3% is represented by direct costs. 
The major direct costs are related with 
patients’ out-of-pocket costs (invest-
ments and informal care), 43.5% of the 
direct costs. 
The study of Ara et al. (10), which com-
pares the direct healthcare costs subdi-
viding the patients according to disease 
severity in moderate (BASDAI <4.0/
BASFI <4.0), severe (BASDAI 4.0-6.0/
BASFI 4.0-6.0), and very severe (BAS-
DAI≥6.0)/BASFI ≥6.0), afﬁrms that 
the annual cost per patient increases ac-
cording to BASDAI and BASFI scores, 
and reports that in the very severe 
group the direct cost is much higher and 
is partly due to the increased need for 
physiotherapy. In this study costs range 
between £1072 and £3485 according 
to BASDAI, and between £1010 and 
£3544 according to BASFI. 
Interestingly, when AS is compared 
with other rheumatic diseases (7, 8, 18), 
such as ﬁbromyalgia (FM) and chronic 
low back pain (CLBP), direct medical 
costs are similar whereas direct non 
medical costs show important differ-
ences among diseases. 
While direct AS related costs are lower 
than in FM, but higher than in CLBP, 
indirect costs associated to AS are low-
er than those in FM and in CLBP (7).
In the study of Verstappen et al. (8), 
mean total direct costs of AS are lower 
respect to rheumatoid arthritis costs. 
With respect to Rheumatoid Arthritis 
(RA), Psoriatic Arthritis (PsA) and Sys-
temic Lupus Erythematosus (SLE), AS 
presents the third higher direct costs but 
the lower indirect costs (18) and SLE 
occupies the ﬁrst position for direct 
costs related to hospitalisations. 
The evaluation of healthcare and non 
healthcare costs from patient’s perspec-
tive shows another interesting aspect: 
overall mean total annual costs amount 
to €1795 per patient of which 76% is 
represented by income loss (5). The 
higher patient’s cost is observed in The 
Netherlands compared with France and 
Belgium (€2172 vs. €1286 and €988). 
An interesting result is represented by 
the 1.25 hours consumed by the patient 
each day due to the disease.
Quality of life (QoL) represents another 
important outcome treated by Boonen et 
al. (5), Kobelt et al. (14), and Zhu et al. 
(16). In the study of Boonen et al. (5), 
the QoL evaluated with EuroQol ques-
tionnaire does not present differences 
between the countries but after adjust-
ing for socio-demographic and disease 
characteristics it is worse in France and 
in Belgium than in The Netherlands. 
QoL is inﬂuenced by many factors such 
as lower education, presence of periph-
eral arthritis, worse physical function, 
and higher disease activity.
Similarly, a reduced QoL is shown by 
Kobelt et al. (14) and Zhu et al. (16), par-
ticularly in general health and vitality.
Discussion and conclusions 
As many other rheumatic diseases, AS 
has high medical and societal costs and 
the relative weight of AS related costs 
on the all cause related costs is extraor-
dinary large (26-32). 
Indirect costs associated with days of 
absence from work (and the relative 
productivity losses) are the most im-
portant determinant of total costs and 
are related with the high patients’ func-
tional limitations due to AS. 
This fact may also partly explain the 
association between total costs and the 
severity of the disease.
Table I summarises the direct and indi-
rect costs evaluated in different coun-
tries and periods (actualised at $2012) 
according to the consumer price index.
It has to be noted that different pay-
ments and reimbursement regimes may 
impact on the amount and distribution 
of indirect costs (31). 
For instance, in the US system, charac-
terised by a predominant private insur-
ance reimbursement mechanism, indi-
rect costs AS related result three times 
higher than direct costs. On the contrary, 
in those countries in which a public re-
imbursement regime prevails, direct and 
indirect costs are more comparable. 
A possible explanation for these differ-
ent results may reside in the capability 
of a country of actually measuring pro-
ductivity losses and indirect costs, and 
of compensating those losses. 
From a public payer point of view, low 
indirect costs without other indicators 
could be due to an underestimation of 
this cost dimension rather than being a 
sign of efﬁciency in AS care. As a con-
sequence, indirect costs may be a net 
loss for patients that nobody can repay. 
On the contrary, a private insurance re-
imbursement regime can induce play-
ers to better deﬁne, select and actually 
identify indirect costs. Future studies 
and analysis are required to test this hy-
pothesis as well as to evaluate in detail 
– and in an international comparative 
way – the burden of AS (33).
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